Janus kinase-Signal Transducer and Activator of Transcription signaling pathway (JAK-STAT pathway) (JAK-STAT pathway)

The Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling pathway is a fundamental mechanism by which extracellular chemical signals, such as cytokines and growth factors, are transmuted into a biological response (Rawlings et al., 2004, Journal of Cell Science). In the host immune system, this pathway is critical for maintaining the balance between T helper 1 (Th1) and T helper 2 (Th2) cell populations. Th1 differentiation is primarily driven by IL-12 and IFN-gamma signaling through JAK2/TYK2 and JAK1/2 respectively, while Th2 differentiation is mediated by IL-4 signaling through JAK1/3 (Seif et al., 2017, Journal of Biological Regulators and Homeostatic Agents). Dysregulation of this Th1/Th2 balance is a hallmark of numerous immune-mediated diseases; for instance, Th1 overactivity is linked to rheumatoid arthritis and Crohn's disease, whereas Th2 dominance is associated with atopic dermatitis and asthma (O'Shea et al., 2013, Nature Reviews Drug Discovery). Therapeutic targeting of this pathway involves JAK inhibitors (JAKinibs), which are small molecules that bind to the ATP-binding site of the JAK kinase domain, effectively blocking the phosphorylation of STAT proteins and subsequent gene transcription (Villarino et al., 2017, Nature Immunology). These drugs, such as tofacitinib and baricitinib, have revolutionized the treatment of autoimmune conditions by modulating the cytokine-driven immune response (Flanagan et al., 2010, Journal of Medicinal Chemistry).

Other names

JAK-STAT signaling cascadeTh1/Th2 balance regulationCytokine-JAK-STAT signaling axis

Inhibition of Janus kinase (JAK) enzymatic activity prevents the phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins, thereby blocking the signal transduction of various pro-inflammatory cytokines and modulating the differentiation and activity of Th1 and Th2 cells.